JPRN-UMIN000007643已完成2 期
Phase2 study of platinum doublet with pemetrexed in non-squamous non-small cell lung cancer with brain metastases. - NJLCG1202
orth Japan Lung Cancer Study Group0 个研究点目标入组 32 人开始时间: 2012年4月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Symptomatic brain metastases 2) Radiotherapy for brain metastases 3) Interstitial lung disease or lung fibrosis detectable or chest X-ray 4) Taking systematic administration of steroid for more than 4 weeks 5) Pleural or cardiac effusion that needs to drain 6) Severe comorbidities 7) Active co-existent malignancies 8) Pregnant patients 9) Other conditions inadequate for this study
研究者
相似试验
已完成
2 期
Phase II study of Platinum-Based Doublet Chemotherapy plus Atezolizumab, in completely resected, p-stage II-IIIA NSCLC patients harboring EGFR mutation. (WJOG11719L Investigator-Initiated Clinical Trial)JPRN-jRCT2080224772obuyuki Yamamoto (Coordinating Investigator)18
进行中（未招募）
1 期
Platinum-doublet chemotherapy combined with nivolumab as first treatment for unresectable, locally advanced or metastatic neuroendocrine neoplasms of the stomach, intestines or pancreas or of unknown origin.EUCTR2019-001546-18-ESGrupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)38
已完成
2 期
Phase II study of pemetrexed or pemetrexed plus bevacizumab for previously untreated elderly non-squamous non-small cell lung cancerJPRN-UMIN000008771ung Oncology Group in Kyushu, Japan (LOGIK)82
招募中
1 期
A Phase 2 study of Carboplatin plus Pemetrexed plus Bevacizumab as first-line therapy for stage3B/4 non-squamous non-small-cell lung cancerung CancerJPRN-UMIN000005143Dokkyo Medical University30
已完成
2 期
Phase 2 study of Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer without EGFR Mutation (CJLSG0906)JPRN-UMIN000003393Central Japan Lung Study Group53